February 2nd 2023

A simple mechanism for integration of quorum sensing and cAMP signalling in *V. cholerae*

Lucas M. Walker[1], James R.J. Haycocks[1], Julia C. van Kessel[2], Triana N. Dalia[2], Ankur B. Dalia[2] and David C. Grainger[1*]

[1]School of Biosciences, University of Birmingham, Edgbaston B15 2TT, UK.

[2]Department of Biology, Indiana University, Bloomington, Indiana, USA.

**for correspondence*

d.grainger@bham.ac.uk

Tel: +44 (0)121 414 5437

ABSTRACT

Many bacteria use quorum sensing to control changes in lifestyle. The process is regulated by microbially derived "autoinducer" signalling molecules, that accumulate in the local environment. Individual cells sense autoinducer abundance, to infer population density, and alter their behaviour accordingly. In *Vibrio cholerae*, quorum sensing signals are transduced by phosphorelay to the transcription factor LuxO. Unphosphorylated LuxO permits expression of HapR, which alters global gene expression patterns. In this work, we have mapped the genome-wide distribution of LuxO and HapR in *V. cholerae*. Whilst LuxO has a small regulon, HapR targets 32 loci. Many HapR targets coincide with sites for the cAMP receptor protein (CRP) that regulates the transcriptional response to carbon starvation. This overlap, also evident in other *Vibrio* species, results from similarities in the DNA sequence bound by each factor. At shared sites, HapR and CRP simultaneously contact the double helix and binding is stabilised by direct interaction of the two factors. Importantly, this involves a CRP surface that usually contacts RNA polymerase to stimulate transcription. As a result, HapR can block transcription activation by CRP. Thus, by interacting at shared sites, HapR and CRP integrate information from quorum sensing and cAMP signalling to control gene expression.

INTRODUCTION

Vibrio cholerae is a Gram-negative bacterium responsible for the human disease cholera[1]. Estimates suggest 3 million annual infections, of which 100 thousand are fatal[2]. Most disease instances are attributed to the El Tor *V. cholerae* biotype, which is responsible for the ongoing 7th cholera pandemic[3]. Globally, over 1 billion people inhabit areas of endemicity and future climatic change is likely to exacerbate the risk of illness[2,4]. The success of *V. cholerae* as a pathogen is underpinned by an ability to colonise both aquatic ecosystems and the human intestinal tract[1]. In waterways, *V. cholerae* prospers by forming biofilms on arthropod exoskeletons. Degradation of these chitinous surfaces ultimately liberates *N*-acetylglucosamine (GlcNAc) for metabolism by the microbe[5]. Upon ingestion by a human host, *V. cholerae* express genetic determinants for acid tolerance, intestinal colonisation, and virulence. Diverse transcription factors regulate the transition and respond to signals including bile[6], temperature[7], nucleotide second messengers[8,9], and chitin availability[5]. Understanding these regulatory networks is important to determine how *V. cholerae* can switch between environments to cause disease outbreaks[3,10,11].

Quorum sensing is key for the transition of *V. cholerae* between ecological niches[12]. Briefly, *V. cholerae* produce at least 3 autoinducer (AI) signalling molecules: cholera AI-1 (CAI-1), AI-2, and 3,5-dimethylpyrazin-2-ol (DPO)[13]. In the environment, these compounds are detected by receptors in neighbouring cells and indicate population density. Importantly, whilst AI-2 and DPO are produced by multiple bacterial species, CAI-1 is only made by other members of the *Vibrio* genus[14]. Thus, *V.*

cholerae can determine the crude composition of bacterial populations. In the absence of their cognate AIs, when population density is low, the receptors for CAI-I and AI-2 target the transcription factor LuxO for phosphorylation via a phosphorelay system[13,15,16]. When phosphorylated, LuxO upregulates the production of four small quorum regulatory RNAs (Qrrs)[17]. In turn, the Qrrs control expression of two global transcription factors: AphA and HapR[17–19]. Importantly, whilst AphA production is activated by Qrrs, synthesis of HapR is repressed. Hence, AphA and HapR control gene expression at low and high cell density respectively[13,19]. A simplified outline of the LuxO dependent regulatory pathway for HapR is illustrated in Figure 1a.

Identified as a regulator of *hapA*, required for *V. cholerae* migration through intestinal mucosa, HapR is a TetR-family member that binds DNA as a homodimer via a N-terminal helix-turn-helix motif[20,21]. Many clinical isolates of pandemic *V. cholerae* have lost the ability to properly express HapR and this may indicate adaptation to a more pathogenic lifestyle[3,10,22]. In *V. cholerae*, HapR regulates the expression of ~100 genes to promote 'group behaviours' including natural competence, repression of virulence genes, and escape from the host intestinal mucosa[23]. In other *Vibrio* spp., equivalent regulons are larger. For example, LuxR in *Vibrio harveyi* regulates over 600 genes[24]. Expression of HapR can be influenced by other factors. In particular, cAMP receptor protein (CRP), a regulator that controls metabolism of alternative carbon sources, including chitin, upregulates HapR[25]. In this study, we used chromatin immunoprecipitation and DNA sequencing (ChIP-seq) to identify direct DNA binding targets of HapR and its upstream regulator, LuxO. We show that the degenerate DNA consensus bound by HapR frequently overlaps targets for CRP. At such sites, HapR and CRP co-operatively bind offset faces of the double helix. Strikingly, this occludes a key CRP surface required to activate transcription. This simple mechanism allows *V. cholerae* species to integrate quorum sensing, and cAMP signalling, in the control of gene expression.

RESULTS

Genome-wide DNA binding by HapR and LuxO in Vibrio cholerae

Whilst the impact of HapR on global gene expression in *V. cholerae* has been investigated, it is not known which HapR responsive genes are directly controlled by the protein[23]. Similarly, the extent of the direct LuxO regulon is unknown. Hence, we sought to map the binding of LuxO and HapR across the *V. cholerae* genome. To facilitate this, *luxO* and *hapR* were cloned in plasmids pAMCF an pAMNF respectively. The resulting constructs, encoding LuxO-3xFLAG or 3xFLAG-HapR, were used to transform *V. cholerae* strain E7946. In subsequent ChIP-seq experiments, anti-FLAG antibodies were used to select fragments of the *V. cholerae* genome bound with either LuxO or HapR. The derived binding profiles are shown in Figure 1b. In each plot, genes are shown as blue lines (outer two tracks) whilst the LuxO and HapR binding signals are red and green respectively (inner two tracks). Examples of individual binding peaks for each factor are shown in Figure 1c. In total, we identified 5 and 32 peaks

for LuxO and HapR binding respectively (Table 1). Previous work identified targets for LuxO adjacent to genes encoding the 4 Qrr sRNAs. We recovered all of these known LuxO targets, and an additional binding site was identified between *VC1142* and *VC1143*. These divergent genes encode cold shock-like protein CspD, and the Clp protease adaptor protein, ClpS, respectively. Note that the LuxO binding signal at this locus is small, compared to the *qrr*1-4 targets (Figure S1). To identify the sequence bound by LuxO, DNA regions overlapping LuxO binding peaks were inspected using MEME. The motif identified matches the known consensus for LuxO binding and was found at all LuxO targets (Table 1 and Figure 1d)[26]. The positions of LuxO binding sites with respect to genes, and the functions encoded by these genes, are summarised in Figures 1e and 1f respectively. Of the 32 peaks for HapR binding, 4 correspond to previously identified direct targets (*hapR*[27], *VC0241*[28], *VC1851*[29] and *VCA0148*[28]). Similarly, a DNA motif common to all HapR ChIP-seq peaks matched prior descriptions of the DNA target for HapR (Figure 1d). Occurrences of this HapR binging motif were most frequent in the 200 bp preceding a gene start codon (Figure 1e). Most often, the genes adjacent to HapR binding peaks encode protein functions related to metabolism, motility, and chemotaxis (Figure 1f). Overall, our data suggest that LuxO primarily regulates gene expression via the 4 Qrr sRNA molecules. Conversely, the genome-wide distribution of HapR is consistent with that of a global gene regulator with many undefined regulatory roles.

HapR is a direct regulator of transcription at many target sites

We focused our attention on new HapR target promoters where adjacent coding sequence could be used to predict encoded protein function. For these 24 targets, regulatory DNA was cloned upstream of *lacZ* in plasmid pRW50T. Recombinants were then transferred to *V. cholerae* E7946, or the Δ*hapR* derivative, by conjugation. Strains generated were cultured overnight before β-galactosidase activities were determined. The results are shown in Figure 2a. Promoters were categorised as inactive, unresponsive, repressed or activated by HapR. We identified 2 and 7 promoters subject to activation and repression by HapR respectively. Of the remaining promoters, 7 were inactive and 11 unresponsive to HapR in our conditions. Next, the 9 promoter DNA fragments responsive to HapR *in vivo* were cloned upstream of the λ*oop* terminator in plasmid pSR. The resulting constructs were then provided to housekeeping *V. cholerae* RNA polymerase, as templates for *in vitro* transcription, in the presence and absence of HapR. The results are shown in Figure 2b where the expected size of transcripts terminated by λ*oop* are marked with blue triangles[30]. Recall that the *VC1375* and *VC1403* promoters were activated by HapR *in vivo* (Figure 1a). Consistent with this, HapR also activated the *VC1375* promoter *in vitro* (Figure 3b, lanes 43-47). However, HapR did not activate *in vitro* transcription from the *VC1403* promoter (Figure 3b, lanes 48-53). Indeed, interpretation of these data were hampered because the location of the *VC1403* transcription start site (TSS) is not known[30]. Of the 7 promoters repressed by HapR *in vivo*, we observed repression in 6 cases *in vitro* (*hapR*, *VC0585*, *VC2352*, *VCA0219*, *VCA0663*

and *VCA0960*) (lanes 7-42). Conversely, the *murQP* promoter (P*murQP*) subject to repression by HapR *in vivo*, generated no transcript *in vitro* (lanes 1-6).

Transcription from the murQP *promoter requires CRP* in vivo *and* in vitro

The *murQP* operon encodes functions important for recycling of peptidoglycan. Briefly, cell wall derived *N*-acetylmuramic acid (MurNAc) is transported across the inner membrane, and simultaneously phosphorylated, by the phosphotransferase system dependent permease MurP. Resulting MurNAc-6P is hydrolysed by MurQ to generate *N*-acetylglucosamine 6-phosphate (GlcNAc-6P). Intriguingly, GlcNAc-6P can also be derived from chitin break down and this coincides with expression of HapR. Hence, we focused on understanding the role of HapR bound upstream of *murPQ*. The HapR ChIP-seq binding signal at the *murQP* locus is shown in Figure 3a and the associated regulatory region is shown in Figure 3b. The centre of the ChIP-seq peak for HapR is marked by an asterisk and the predicted binding site is highlighted green. We reasoned that our inability to detect transcription from P*murQP* *in vitro* was likely because an undefined transcriptional activator is absent (Figure 2b). Inspection of the DNA sequence upstream of *murQP* identified a close match to the consensus binding site for CRP (5'-TGTGA-N_6-TCACA-3'). Furthermore, this sequence was located 41.5 bp upstream, of the *murQP* TSS (Figure 3b). This is a common scenario for CRP dependent transcription activation[31]. To measure binding of CRP to the *murQP* regulatory region we used electrophoretic mobility shift assays (EMSAs). Consistent with our prediction, CRP bound to the *murQP* regulatory DNA (Figure 3c, lanes 1 and 2). To confirm that we had correctly identified the binding site for CRP we made a series of P*murQP* derivatives. The Δ183 and Δ211 DNA fragments have large upstream deletions (sites of truncation are shown by inverted triangles in Figure 3b, which mark the 5' end of the remaining promoter DNA) but still bind CRP (Figure 3c, lanes 3-6). Conversely, point mutations -35g and -49g, within the CRP site, prevent binding (Figure 3c, lanes 7-8). To determine the impact of CRP on P*murQP* activity we first used *in vitro* transcription assays (Figure 3d). Addition of CRP to reactions resulted in production of an RNA from P*murQP*. We observed similar CRP dependence *in vivo* using β-galactosidase assays (Figure 3e, compare wild type promoter activity with and without CRP). Furthermore, in wild type cells, the -35g and -49g mutations reduced promotor activity whilst the Δ183 and Δ211 truncations did not (Figure 3e). We note that the Δ211 derivative is much more active than the starting promoter DNA sequence, but transcription remains totally dependent on CRP. Most likely, the truncation removes a repressive DNA element upstream of the core promoter.

HapR and CRP bind a shared DNA site at the murQP *promoter*

At P*murQP*, the DNA site for CRP is completely embedded within the predicted HapR binding sequence (Figure 3b). To better understand this unusual configuration, we used DNAseI footprinting. The results are shown in Figure 4a. Lane 1 shows the pattern of DNAseI digestion in the absence of

bound protein. In the presence of CRP (lanes 2-4) a footprint was observed between positions -29 and -59 bp relative to the *murQP* TSS. As is usual for CRP, and a consequence of DNA bending, the footprint comprised protection from, and hypersensitivity to, DNAse I attack. Three distinct sites of DNAseI hypersensitivity are marked by orange arrows alongside lane 4 in Figure 4a. The pattern of DNAse I digestion in the presence of HapR is shown in lanes 5-8. The footprint due to HapR binding exactly overlaps the region bound by CRP and results in complete protection of the DNA from digestion between positions -29 and -58 (green bar adjacent to lane 8). We also observed changes in the relative intensity of bands upstream of the HapR site between promoter positions -60 and -80. We speculate that this may result from changes in DNA conformation. Importantly, there was one further subtle difference between HapR and CRP induced banding patterns. Namely, in the presence of HapR, a band was observed at position -58 (see green triangle adjacent to lane 8). With CRP, a band was instead observed at position -59 (compare lanes 2-4 with 5-8). In a final set of assays, we examined addition of CRP and HapR in unison. We reasoned that 3 outcomes were possible. First, one of the two protein factors could outcompete the other. This should result in a DNAse I digestion pattern identical to either the individual CRP or HapR footprint. Second, some DNA fragments in the reaction could be bound by CRP and others by HapR. In this case, a mixed DNAse I digestion pattern, containing all features of the individual footprints due to CRP and HapR, should occur. Third, CRP and HapR could bind simultaneously. This might generate a DNAse I digestion pattern with similarities to the CRP and HapR footprints. However, accessibility of the nucleic acid to DNAse I would likely be altered in some way, with unpredictable outcomes. The result of the experiment was analysed in lanes 9-12. The binding pattern matched only some aspects of the individual footprints for CRP and HapR. Hence, we observed 2 of the 3 DNAse I hypersensitivity sites due to CRP binding. Changes in the banding pattern upstream of the binding sequence, due to HapR, were also detected. We did not observe the band at position -58 detected with HapR alone. Rather, we observed a band at position -59. An additional band at position -26 (black triangle adjacent to lane 12) was unique to these reactions. We conclude that HapR and CRP recognise the same section of the *murQP* regulatory region and may bind in unison.

HapR and CRP bind the murQP *promoter co-operatively*

Fragments of the *murQP* regulatory DNA, simultaneously bound by CRP and HapR, are expected to have distinct migratory properties during electrophoresis. Thus, we compared binding of CRP and/or HapR using EMSAs. The results are shown in Figure 4b. As expected, addition of CRP to reactions caused a distinct shift in electrophoretic mobility (lanes 1-5). Comparatively, at the concentration used, HapR bound the DNA fragment poorly; we observed only smearing of the free DNA at the highest HapR concentration tested (lanes 6-10). The binding pattern due to HapR was dramatically different if DNA was pre-bound with CRP (lanes 11-15). In this scenario, even low concentrations of added HapR were sufficient to generate a super-shifted nucleoprotein complex (lanes 11-15). These data are consistent with HapR having a higher affinity for CRP-P*murQP* than P*murQP* alone. Hence, HapR and

CRP bind the *murQP* regulatory region co-operatively. A mundane explanation is that increased molecular crowding, upon CRP addition, increases the effective concentration of HapR. To exclude this possibility, we did two further sets of EMSA experiments. In the first set of assays, CRP was added at a lower concentration. Thus, some DNA remained unbound (Figure 4c, lanes 1 and 2). Hence, when added to such reactions, HapR could bind either the free DNA or the CRP-DNA complex. Consistent with HapR preferentially binding the latter, all of the CRP-DNA complex was super shifted upon HapR addition. Conversely, the free DNA remained unbound (compare lanes 2 and 4). In equivalent experiments, with point mutations -49g and -35g in the CRP site, neither CRP or HapR were able to bind the DNA (lanes 5-8). In a second set of tests, we used the *hapR* regulatory DNA that binds HapR but not CRP. If CRP addition increased the effective concentration of HapR, this should result in much tighter HapR binding to the *hapR* promoter. However, this was not the case (Figure S2). Taken together, our data are consistent with CRP and HapR co-operatively binding the same DNA locus at the *murQP* promoter region.

HapR represses CRP dependent transcription from the murQP *promoter in vivo* and *in vitro*

Recall that, in the absence of CRP, P*murQP* is inactive *in vitro* (Figures 2b and 3d). Furthermore, the promoter is subject to repression by HapR *in vivo* (Figure 2a). An explanation consistent with both observations is that HapR directly counteracts CRP mediated activation. To test this, we used *in vitro* transcription assays (Figure 4d). As expected, addition of CRP activated *murQP* transcription (lanes 1-4) and this was blocked by addition of HapR (lanes 5-8). We also repeated our prior *lacZ* fusion experiments, using the Δ211 P*murQP* derivative, and *V. cholerae* E7946 lacking *crp* and/or *hapR*. The result is shown in Figure 4e. Deletion of *hapR* caused increased transcription from P*murQP* only when CRP was present. Hence, HapR also represses CRP dependent *murQP* transcription *in vivo*.

Binding sites for CRP and HapR overlap in a specific configuration genome-wide

Both CRP and HapR bind the same DNA region upstream of *murPQ*. This suggests similar nucleic acid sequences are recognised by each factor. Figure 5a shows an alignment of DNA logos, derived from CRP[9] (top) and HapR (bottom) ChIP-seq targets. The two motifs have features in common that align best when the logo centres are offset by 1 base pair. This is consistent with the arrangement of binding sites upstream of *murPQ* (Figure 3b). To understand the importance of this configuration we first took a bioinformatic approach. The DNA sequences logos shown in Figure 5a were used to create position weight matrices (PWMs) describing either the CRP or HapR binding site. We then searched the *V. cholerae* genome, using each PWM, and calculated the distance between identified CRP and HapR sites. The data for all sites within 100 bp of each other is shown in Figure 5b (top panel). In all cases, the CRP and HapR targets were offset by 1 bp. We then repeated the analysis after randomising the *V. cholerae* genome sequence (bottom panel). The number of overlapping targets was reduced 7-fold. An equivalent analysis of the *V. harveyi* genome produced similar results (Figure S3). Hence, sites for CRP

and HapR have a propensity to coincide in a specific configuration. That such sites are found more frequently in native genome sequences, compared to those first randomised, suggests selection during genome evolution. We next sought to understand how this arrangement might permit simultaneous and co-operative binding of CRP and HapR.

A structural model of the DNA-CRP-HapR ternary complex

To understand organisation of the DNA-CRP-HapR ternary complex we used structural modelling. The *V. cholerae* CRP protein is 96 % identical to the equivalent factor in *Escherichia coli*. Similarly, the *Staphylococcus aureus* factor QacR is 50 % similar to *V. cholerae* HapR. Previously, structural biology tools were used to investigate *E. coli* CRP, and *S. aureus* QacR, bound with their cognate DNA targets. We used this information to build a model for the DNA-CRP-HapR ternary complex. Importantly, we ensured that the CRP and HapR binding centres were offset by 1 bp. When aligned in this way, CRP and HapR recognise the same section of DNA via different surfaces of the double helix. We examined the model in the context of our DNAse I footprinting data. Recall that CRP binding upstream of *murPQ* induces three sites of DNAse I hypersensitivity (Figure 4a). These correspond to positions -47, -38 and -34 with respect to the *murQP* TSS. Figure S4 shows these positions highlighted in the context of our model. In the presence of CRP alone, all sites are surface exposed but position -34 is partially occluded by CRP (Figure S4a). This likely explains why positions -47 and -38 are more readily cleaved by DNAse I (Figure 4a). With both CRP and HapR, position -34 was completely protected from DNAse I attack (Figure 4a). Consistent with the footprinting data, our model indicates that position -34 is almost completely hidden upon binding of HapR (Figure S4b). Conversely, access to positions -47 and -38 is not altered (Compare Figures S4a and S4b).

Co-operative binding with HapR requires CRP residue E55

Co-operative DNA binding by transcription factors can result from their direct interaction[32–34]. In our model, a negatively charged surface of CRP (including residue E55) is in close proximity to positively charged HapR residue R123 (Figure 5c). In initial experiments, we mutated both protein surfaces to remove the charged side chain, or replace the residue with an oppositely charged amino acid. We then investigated consequences for HapR and CRP binding individually at P*murQP* using EMSAs (Figure S5). Whilst the CRP derivatives were able to bind the *murQP* regulatory region normally, HapR variants were completely defective. This is likely because R123 sits at the HapR dimerisation interface. Hence, we focused on understanding the contribution of CRP sidechain E55 to co-operative DNA binding by HapR and CRP using EMSAs. The results are shown in Figure 5d. Both wild type CRP, and CRP^{E55A}, were able to bind the *murQP* regulatory region similarly (lanes 1-4 and 10-13). As expected, HapR bound tightly to the wild type CRP:DNA complex (lanes 5-9). Conversely, HapR had a lower affinity for DNA in complex with CRP^{E55A} (lanes 14-18). This suggests that the E55A mutation in CRP destabilises the interaction with HapR.

*Repression of P*murQP *by HapR requires CRP residue E55*

Residue E55 locates to a negatively charged surface of CRP called Activating Region 3 (AR3). This determinant aids recruitment of RNA polymerase when CRP binds close to the promoter -35 element[35]. Hence, AR3 is likely to be important for activation of P*murQP* (Figure 3b). We inferred that CRP lacking E55 should activate P*murQP* less efficiently but be less sensitive to negative effects of HapR. To test these predictions, we used *in vitro* transcription assays. The results for CRP, CRP^{E55A} and CRP^{E55R} are shown in Figure 5e. All CRP derivatives were able to activate transcription from P*murQP*. However, consistent with an important role for AR3, the ability of the CRP^{E55A} and CRP^{E55R} to activate transcription was impaired (compare lanes 1-5, 10-14 and 19-23). Crucially, whilst HapR reduced transcription dependent on wild type CRP by 50-fold (compare lane 4 with lanes 6-9) only a 2-fold effect of HapR was observed with CRP^{E55A} (compare lane 13 with lanes 15-18). In the presence of CRP^{E55R}, HapR was even less effective (compare lane 22 with lanes 24-27).

High cell density locked V. cholerae are defective for growth on MurNAc

Phosphorylated LuxO activates expression of the Qrr sRNAs that inhibit *hapR* expression at low cell density (Figure 1a). Consequently, deletion of *luxO* causes constitutive expression of HapR. Thus, Δ*luxO V. cholerae* are "locked" in a high cell density state[29]. Our model predicts that such strains will be defective for growth using MurNAc as the sole carbon source, as this requires expression of *murQP* that is repressed by HapR. Furthermore, any such defect should be relieved upon deletion of *hapR*. To test this, we constructed strains lacking different combinations of *luxO* and *hapR*. We also tested a *V. cholerae* derivative lacking *murP*[36]. Figure 6a illustrates growth in M9 minimal media, supplemented with MurNAc or glucose, and in Luria Broth. As expected, cells lacking *murP* could not grow when MurNAc was the only carbon source but were not defective in other conditions (compare grey data points in each panel). Cells lacking *hapR*, alone or in combination with *luxO*, had a similar growth defect in all conditions. Strikingly, the *luxO* mutant (high cell density locked), exhibited a growth defect only when MurNAc was the sole carbon source (compare red data points). Specifically, these cells exhibited an extended lag phase in MurNAc. This extended lag phase was not apparent when both *luxO* and *hapR* were deleted, consistent with the effect of *luxO* being mediated by HapR-dependent repression of *murQP*.

Co-operative interactions between HapR and CRP are commonplace

In a final set of experiments, we turned our attention to other sites shared by CRP and HapR (Table 1 and prior work[9]). We selected 5 such targets and examined binding of CRP and HapR using EMSAs. At 1 target, adjacent to *VCA0218*, binding was not co-operative and free DNA remained when both proteins were present (Figure S6). For 4 of the targets, we detected co-operative binding of CRP and HapR, reminiscent of our experiments with P*murQP* DNA (Figure 4). At these loci (adjacent to *VC0102*, *VC1851*, *VCA0663* and *VCA0691*) either HapR or CRP bound poorly to DNA in the absence

of the other protein. However, when both factors were added together, all DNA shifted into a distinct low mobility complex. We conclude that co-operative binding of HapR and CRP to shared targets is common.

DISCUSSION

Previously, two studies have mapped DNA binding by HapR homologs in *Vibrio* species. For *V. harveyi*, van Kessel and co-workers used ChIP-seq to identify 105 LuxR binding targets[37]. At 77 of these sites, LuxR repressed transcription. Using ChIP-seq and global DNAse I footprinting, Zhang *et al*. found 76 LuxR bound regions in *Vibrio alginolyticus*[38]. Regulatory effects were evident for 37 targeted genes, with 22 cases of LuxR mediated repression. In the present study, we identified 32 HapR bound sections of the *V. cholerae* genome. Consistent with prior work, repression of target genes was the most common regulatory outcome. Furthermore, the DNA binding consensus derived here for HapR is almost identical to motifs for LuxR binding in *V. harveyi* and *V. alginolyticus*. Contrastingly, Tsou and colleagues used bioinformatic tools to predict HapR binding in *V. cholerae*[28]. Two different HapR binding motifs were proposed. Both partially match the HapR target sequence proposed here. Most likely, the analysis of Tsou *et al*. was hampered by a paucity of targets from which a full consensus could be derived. We note that our list of 32 HapR targets does not include all known targets. However, on inspection, whilst insufficient to pass our stringent selection criteria, weaker signals for HapR are evident at many such locations (Figure S7). In particular, we note evidence for binding of HapR upstream of *hapA*, which has previously been only inferred (Figure S7b).

Recognition of shared DNA targets provides a simple mechanism for integration of quorum sensing signals, relayed by HapR, and cAMP fluctuations, communicated by CRP. In the example presented here, HapR acts to prevent transcription activation by co-binding the same DNA target with CRP (Figure 4). Hence, at P*murQP*, the function of CRP switches from that of an activator to a co-repressor with HapR (Figure 6b). This regulatory strategy is a logical consequence of *V. cholerae* forming biofilms on chitinous surfaces. At low cell density, rapidly dividing cells must continually remodel their cell wall. In these conditions, HapR is not expressed. Thus, MurQ and MurP are produced and can convert cell wall derived MurNAc to GlcNAc-6P. Conversely, in high cell density scenarios, usually involving adherence to chitin, cells divide infrequently, and remodelling of the cell wall is not required. In addition, GlcNAc-6P can be derived readily from chitin oligosaccharides. Hence, cells locked in the high cell density state are defective for growth when supplied with MurNAc as the sole carbon source (Figure 6a). We suggest that HapR and CRP are likely to coordinate the expression of other metabolic enzymes in a similar way. Interestingly, AphA, another quorum sensing responsive regulator, also acts alongside CRP at many *V. cholerae* promoters[39]. Indeed, AphA and CRP binding sites can overlap but this results in competition between the factors[39]. Together with results presented here, these observations highlight close integration of quorum sensing with gene control by cAMP in *V. cholerae*.

MATERIALS AND METHODS

Strains, plasmids and oligonucleotides

Strains, plasmids and oligonucleotides used in this study are listed in Table S1. All *V. cholerae* strains are derivatives of E7946[40]. Chromosomal deletions were made using the pKAS32 suicide plasmid for allelic exchange[41,42] or via splicing-by-overlap-extension PCR and chitin-induced natural transformation[43]. The *E. coli* strain JCB387 was used for routine cloning[44]. Plasmids were transferred into *V. cholerae* by either conjugation or transformation as described previously[9,39].

ChIP-seq and bioinformatics

Chromatin immunoprecipitation was done as in prior work[39] using strain E7946, carrying plasmid pAMCF-*luxO* or pAMNF-*hapR*. In both cases, control experiments were done using the equivalent plasmid with no gene insert. Note that both plasmids drive low level constitutive expression of 3xFLAG transcription factor derivatives[45]. Lysates were prepared from mid-log phase cultures, incubated with shaking at 37 °C. Following sonication, the protein-DNA complexes were immunoprecipitated with an anti-FLAG antibody (Sigma) and Protein A sepharose beads. Immunoprecipitated DNA was blunt-ended, A- tailed, and ligated to barcoded adaptors before elution and de-crosslinking. ChIP-seq libraries were then amplified by PCR and purified. Library quality was assessed using an Agilent Tapestation 4200 instrument and quantity determined by qPCR using an NEBnext library quantification kit (NEB). Libraries were sequenced as described previously[45] and reads are available from ArrayExpress using accession code E-MTAB-11906. Single-end reads, from two independent ChIP-seq experiments for each strain, were mapped to the reference *V. cholerae* N16961 genome (chromosome I: NC_002505.1 and chromosome II: NC_002506.1) with Bowtie 2[46]. The read depth at each position of the genome was determined for each BAM file using multibamsummary. Each binding profile was then normalised to an average genome-wide read depth of 1 read per base. Following normalisation, the average read depth per base for each pair of replicates was calculated. The resulting files were used to generate the circular plots in Figure 1 using DNAplotter[47]. For peak selection, the files were viewed as graphs using the Artemis genome browser[48]. After visually identifying an appropriate cut-off, peaks were selected using the "create features from graph" tool. For HapR, the window size, minimum feature size, and cut-off value were 100, 100 and 10 respectively. For LuxO, the equivalent values were 100, 100 and 4. The mid-point of features selected in this way was set as the peak centre. In each case, 300 bp of sequence from the peak centre was selected and the combined

set of such sequences for each factor were analysed using MEME to generate DNA sequence logos[49].

β-galactosidase assays

Promoter DNA was fused to *lacZ* in plasmid pRW50T that can be transferred from *E. coli* to *V. cholerae* by conjugation[9]. Assays of β-galactosidase activity were done according to the Miller method[50]. Bacterial cultures were grown at 37 °C with shaking in LB broth, supplemented with appropriate antibiotics, to mid-log phase. Values shown are the mean of three independent experiments and error bars show the standard deviation.

Proteins

We purified *V. cholerae* CRP and RNA polymerase as described previously[9,39]. To generate HapR, *E. coli* T7 Express cells were transformed with plasmid pHis-tev-HapR, or derivatives, which encodes HapR with a His_6 tag and intervening site for the tobacco etch virus protease protease. Transformants were cultured in 40 ml LB overnight, then subcultured in 1 L of LB, with shaking at 37 ºC. When subcultures reached midlog phase they were supplemented with 400 mM IPTG for 3 hours. Cells were then collected by centrifugation, resuspended in 40 ml of buffer 1 (40 ml 25 mM Tris-HCl pH 7.5, 1 mM EDTA and 1 M NaCl) and lysed by sonication. Inclusion bodies, recovered by centrifugation, were resuspended with 40 ml of buffer 2 (25 mM Tris-HCl pH 8.5 and 4 M urea) before the remaining solid material was again recovered and then solubilised using 40 ml of buffer 3 (25 mM Tris-HCl pH 8.5 and 6 M guanidine hydrochloride). Cleared supernatant was applied to a HisTrap HP column (GE healthcare) equilibrated with buffer A (25 mM Tris-HCl pH 8.5 and 1 M NaCl). To elute His_6-HapR, a gradient of buffer B (25 mM Tris-HCl pH 8.5, 1 M NaCl and 1 M imidazole) was used. Fractions containing His_6-HapR were pooled and the protein was transferred into buffer X (50 mM HEPES, 1 M NaCl, 1 mM DTT, 5 mM EDTA and 0.1 mM Triton X-100) by dialysis. Finally, we used Vivaspin ultrafiltration columns to reduce sample volume. The concentration of His_6-HapR was then determined.

in vitro *transcription assays*

Experiments were done using our prior approach[39]. Plasmid templates were isolated from *E. coli* using Qiagen Maxiprep kits. Each *in vitro* transcription assay contained 16 μg/ml DNA template in 40 mM Tris pH 7.9, 5 mM MgCl2, 500 μM DTT, 50 mM KCl, 100 μg/ml BSA, 200 μM ATP/GTP/CTP, 10 μM UTP and 5 μCi α-P32-UTP. Purified HapR and CRP were added at the indicated concentrations prior to the reaction start point. In experiments where CRP was used, the protein was incubated with cAMP 37 ºC prior to addition. Transcription was instigated by addition of RNA polymerase holoenzyme prepared in advance by incubation of the core enzyme with a 4-fold excess of σ^{70} for 15 minutes at room temperature. After 10 minutes incubation at 37 °C, reactions were stopped by the

addition of an equal volume of formamide containing stop buffer. Reactions were resolved on an 8% (*w/v*) denaturing polyacrylamide gel, exposed on a Bio-Rad phosphor screen then visualised on a Bio-Rad Personal Molecular Imager. The quantify transcript levels, we measured the intensity of bands corresponding to RNAI and the RNA of interest using Quantity One software. After subtracting background lane intensity, we calculated the RNA of interest to RNAI ratio. The maximum ratio was set to 100 % activity with other ratios shown a percentage of this maximum.

Electrophoretic mobility shift assays and DNAse I footprinting

Promoter DNA fragments were excised from plasmid pSR and end-labelled with γ32-ATP using T4 PNK (NEB). EMSAs and DNase I footprints were done as previously described [39]. Full gel images are shown in Figure S8.

Structural modelling

The model of the ternary DNA-CRP-HapR complex was generated in PyMOL by aligning PDB depositions 1jt0 (QacR-DNA complex) and 6pb6 (CRP-DNA complex). Alignments were done manually and guided by the relative two-fold centres of symmetry for each complex. Each structure was positioned so that their DNA base pairs overlapped and binding centres were offset by 1 base pair. The Mutagenesis function of PyMOL was used to replace QacR sidechain K107, equivalent to HapR R123[20], with an arginine residue. The double helix of the QacR DNA complex is hidden in the final model.

REFERENCES

1. Nelson, E. J., Harris, J. B., Morris, J. G., Calderwood, S. B. & Camilli, A. Cholera transmission: The host, pathogen and bacteriophage dynamic. *Nature Reviews Microbiology* vol. 7 693–702 (2009).
2. Ali, M., Nelson, A. R., Lopez, A. L. & Sack, D. A. Updated Global Burden of Cholera in Endemic Countries. *PLoS Negl. Trop. Dis.* **9**, (2015).
3. Domman, D. *et al.* Integrated view of Vibrio cholerae in the Americas. *Science* **358**, 789–793 (2017).
4. Asadgol, Z., Mohammadi, H., Kermani, M., Badirzadeh, A. & Gholami, M. The effect of climate change on cholera disease: The road ahead using artificial neural network. *PLoS One* **14**, e0224813 (2019).
5. Meiborn, K. L. *et al.* The Vibrio cholerae chitin utilization program. *PNAS* **101**, 2524–2529 (2004).
6. Hung, D. T. & Mekalanos, J. J. Bile acids induce cholera toxin expression in Vibrio cholerae in a ToxT-independent manner. *PNAS* **102**, 3028–3033 (2005).
7. Weber, G. G., Kortmann, J., Narberhaus, F. & Klose, K. E. RNA thermometer controls

temperature-dependent virulence factor expression in Vibrio cholerae. *PNAS* **111**, 14241–14246 (2014).

8. Krasteva, P. V. *et al.* Vibrio cholerae vpst regulates matrix production and motility by directly sensing cyclic di-GMP. *Science* **327**, 866–868 (2010).

9. Manneh-Roussel, J. *et al.* Camp receptor protein controls Vibrio cholerae gene expression in response to host colonization. *MBio* **9**, (2018).

10. Kamareddine, L. *et al.* Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. *Nat. Microbiol.* **3**, 243–252 (2018).

11. Weill, F.-X. *et al.* Genomic history of the seventh pandemic of cholera in Africa. *Science* **358**, 785–789 (2017).

12. Eickhoff, M. J. & Bassler, B. L. SnapShot: Bacterial Quorum Sensing. *Cell* vol. 174 1328-1328.e1 (2018).

13. Mukherjee, S. & Bassler, B. L. Bacterial quorum sensing in complex and dynamically changing environments. *Nature Reviews Microbiology* vol. 17 371–382 (2019).

14. Henke, J. M. & Bassler, B. L. Three parallel quorum-sensing systems regulate gene expression in Vibrio harveyi. *J. Bacteriol.* **186**, 6902–6914 (2004).

15. Freeman, J. A. & Bassler, B. L. A genetic analysis of the function of LuxO, a two-component response regulator involved in quorum sensing in Vibrio harveyi. *Mol. Microbiol.* **31**, 665–677 (1999).

16. Freeman, J. A. & Bassler, B. L. Sequence and function of LuxU: A two-component phosphorelay protein that regulates quorum sensing in Vibrio harveyi. *J. Bacteriol.* **181**, 899–906 (1999).

17. Lenz, D. H. *et al.* The small RNA chaperone Hfq and multiple small RNAs control quorum sensing in Vibrio harveyi and Vibrio cholerae. *Cell* **118**, 69–82 (2004).

18. Shao, Y. & Bassler, B. L. Quorum-sensing non-coding small RNAs use unique pairing regions to differentially control mRNA targets. *Mol. Microbiol.* **83**, 599–611 (2012).

19. Rutherford, S. T., Van Kessel, J. C., Shao, Y. & Bassler, B. L. AphA and LuxR/HapR reciprocally control quorum sensing in vibrios. *Genes Dev.* **25**, 397–408 (2011).

20. De Silva, R. S. *et al.* Crystal structure of the Vibrio cholerae quorum-sensing regulatory protein HapR. *J. Bacteriol.* **189**, 5683–5691 (2007).

21. Jobling, M. G. & Holmes, R. K. Characterization of hapR , a positive regulator of the Vibrio cholerae HA/protease gene hap , and its identification as a functional homologue of the Vibrio harveyi luxR gene. *Mol. Microbiol.* **26**, 1023–1034 (1997).

22. Heidelberg, J. F. *et al.* DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. *Nature* **406**, 477–483 (2000).

23. Nielsen, A. T. *et al.* RpoS controls the Vibrio cholerae mucosal escape response. *PLoS Pathog.* **2**, 0933–0948 (2006).

24. Van Kessel, J. C., Rutherford, S. T., Shao, Y., Utria, A. F. & Bassler, B. L. Individual and combined roles of the master regulators apha and luxr in control of the Vibrio harveyi quorum-sensing regulon. *J. Bacteriol.* **195**, 436–443 (2013).
25. Silva, A. J. & Benitez, J. A. Transcriptional regulation of Vibrio cholerae hemagglutinin/protease by the cyclic AMP receptor protein and RpoS. *J. Bacteriol.* **186**, 6374–6382 (2004).
26. Tu, K. C. & Bassler, B. L. Multiple small RNAs act additively to integrate sensory information and control quorum sensing in Vibrio harveyi. *Genes Dev.* **21**, 221–233 (2007).
27. Lin, W., Kovacikova, G. & Skorupski, K. Requirements for Vibrio cholerae HapR binding and transcriptional repression at the hapR promoter are distinct from those at the aphA promoter. *J. Bacteriol.* **187**, 3013–3019 (2005).
28. Tsou, A. M., Cai, T., Liu, Z., Zhu, J. & Kulkarni, R. V. Regulatory targets of quorum sensing in Vibrio cholerae: Evidence for two distinct HapR-binding motifs. *Nucleic Acids Res.* **37**, 2747–2756 (2009).
29. Waters, C. M., Lu, W., Rabinowitz, J. D. & Bassler, B. L. Quorum sensing controls biofilm formation in Vibrio cholerae through modulation of cyclic Di-GMP levels and repression of vpsT. *J. Bacteriol.* **190**, 2527–2536 (2008).
30. Papenfort, K., Förstner, K. U., Cong, J. P., Sharma, C. M. & Bassler, B. L. Differential RNA-seq of Vibrio cholerae identifies the VqmR small RNA as a regulator of biofilm formation. *PNAS* **112**, E766–E775 (2015).
31. Savery, N. J. *et al.* Transcription activation at class II CRP-dependent promoters: Identification of determinants in the C-terminal domain of the RNA polymerase α subunit. *EMBO J.* **17**, 3439–3447 (1998).
32. Wade, J. T., Belyaeva, T. A., Hyde, E. I. & Busby, S. J. W. A simple mechanism for co-dependence on two activators at an Escherichia coli promoter. *EMBO J.* **20**, 7160–7167 (2002).
33. Kallipolitis, B. H., Nørregaard-Madsen, M. & Valentin-Hansen, P. Protein-protein communication: Structural model of the repression complex formed by CytR and the global regulator CRP. *Cell* **89**, 1101–1109 (1997).
34. Meibom, K. L., Kallipolitis, B. H., Ebright, R. H. & Valentin-Hansen, P. Identification of the subunit of cAMP receptor protein (CRP) that functionally interacts with CytR in CRP-CytR-mediated transcriptional repression. *J. Biol. Chem.* **275**, 11951–11956 (2000).
35. Rhodius, V. A. & Busby, S. J. W. Interactions between Activating Region 3 of the Escherichia coli cyclic AMP receptor protein and region 4 of the RNA polymerase σ70 subunit: Application of suppression genetics. *J. Mol. Biol.* **299**, 311–324 (2000).
36. Hayes, C. A., Dalia, T. N. & Dalia, A. B. Systematic genetic dissection of PTS in Vibrio cholerae uncovers a novel glucose transporter and a limited role for PTS during infection of a

mammalian host. *Mol. Microbiol.* **104**, 568–579 (2017).

37. van Kessel, J. C., Ulrich, L. E., Zhulin, I. B. & Bassler, B. L. Analysis of activator and repressor functions reveals the requirements for transcriptional control by LuxR, the master regulator of quorum sensing in Vibrio harveyi. *MBio* **4**, (2013).

38. Zhang, J. *et al.* Binding site profiles and N-terminal minor groove interactions of the master quorum-sensing regulator LuxR enable flexible control of gene activation and repression. *Nucleic Acids Res.* **49**, 3274–3293 (2021).

39. Haycocks, J. R. J. J. *et al.* The quorum sensing transcription factor AphA directly regulates natural competence in Vibrio cholerae. *PLoS Genet.* **15**, e1008362 (2019).

40. Levine, M. M. *et al.* The pathogenicity of nonenterotoxigenic vibrio cholerae serogroup 01 biotype ei tor isolated from sewage water in brazil. *J. Infect. Dis.* **145**, 296–299 (1982).

41. Skorupski, K. & Taylor, R. K. Positive selection vectors for allelic exchange. *Gene* **169**, 47–52 (1996).

42. Dalia, A. B., McDonough, E. K. & Camilli, A. Multiplex genome editing by natural transformation. *PNAS* **111**, 8937–8942 (2014).

43. Dalia, A. B. Natural cotransformation and multiplex genome editing by natural transformation (MuGENT) of vibrio cholerae. in *Methods in Molecular Biology* vol. 1839 53–64 (2018).

44. Page, L., Griffiths, L. & Cole, J. A. Different physiological roles of two independent pathways for nitrite reduction to ammonia by enteric bacteria. *Arch. Microbiol.* **154**, 349–354 (1990).

45. Sharma, P. *et al.* The multiple antibiotic resistance operon of enteric bacteria controls DNA repair and outer membrane integrity. *Nat. Commun.* **8**, 1444 (2017).

46. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359 (2012).

47. Carver, T., Thomson, N., Bleasby, A., Berriman, M. & Parkhill, J. DNAPlotter: circular and linear interactive genome visualization. *Bioinformatics* **25**, 119–120 (2008).

48. Carver, T., Harris, S. R., Berriman, M., Parkhill, J. & Mcquillan, J. A. Artemis: an integrated platform for visualization and analysis of high-throughput sequence-based experimental data. **28**, 464–469 (2012).

49. Bailey, T. L. *et al.* MEME Suite: Tools for motif discovery and searching. *Nucleic Acids Res.* **37**, (2009).

50. Miller, J. *Experiments in molecular genetics*. *Experiments in molecular genetics* (Cold Spring Harbor Laboratory, 1972).

ACKNOWLEDGEMENTS

This work was funded by BBSRC project grant BB/N005961/1 awarded to DCG, a BBSRC MIBTP studentship (BB/M01116X/1, project reference 1898542) awarded to LMW, and grant

R35GM128674 from the National Institutes of Health (to ABD). We thank Kai Papenfort, Jenny Ritchie and Joseph Wade, for commenting on the manuscript prior to submission, and Melanie Blokesch for helpful discussions.

FIGURE LEGENDS

Figure 1: Genome-wide distribution of HapR and LuxO in *Vibrio cholerae*.

a. **Simplified schematic overview of quorum sensing in *Vibrio cholerae*.** At low cell density, expression of HapR is repressed by the Qrr sRNAs that depend on phosphorylated LuxO for activation of their transcription. Arrows indicate activation and bar ended lines indicate repression. For clarity, not all protein factors involved in the cascade have been included.
b. **Binding of LuxO and HapR across both *Vibrio cholerae* chromosomes.** In each plot the outer two tracks (blue) are genes orientated in the forward or reverse direction. The LuxO and HapR ChIP-seq binding signals are shown in red and green. LuxO binding peaks corresponding to the *qrr1-4* loci are indicated. Tick marks are 0.25 Mbp apart.
c. **Example LuxO and HapR ChIP-seq binding peaks.** ChIP-seq coverage plots are shown for individual experimental replicates. Data for LuxO and HapR are in green and red respectively. Signals above or below the horizontal line correspond to reads mapping to the top or bottom strand respectively. Gene are show as block arrows.
d. **Sequence motifs derived from LuxO and HapR binding peaks using MEME.**
e. **Positions of LuxO and HapR binding peaks with respect to genes.** The histograms show the distribution of binding peak centres with respect to the start codon of the nearest gene.
f. **Pie charts showing gene classes targeted by LuxO and HapR.**

Figure 2: HapR is a direct repressor of transcription at many target promoters.

a. **Activity of HapR targeted promoters in the presence and absence of HapR *in vivo*.** The promoter regions of HapR targeted genes were fused to *lacZ* in plasmid pRW50T and constructs used to transform required bacterial strains. was measured in cell lysates taken from *Vibrio cholerae* E7946 (bars) or the Δ*hapR* derivative (open bars). containing the *VC0857* promoter cloned upstream of *lacZ* in pRW50T. Standard deviation is shown for three independent biological replicates. Cells were grown in LB medium. Promoters were classified as inactive if, in both the presence and absence of HapR, β-galactosidase activity was <2-fold higher than the equivalent no insert control.
b. **Activity of HapR targeted promoters in the presence and absence of HapR *in vitro*.** The gel images show results of *in vitro* transcription experiments. The DNA templates were plasmid pSR derivatives containing the indicated regulatory regions. Experiments were done with 0.4 µM RNA polymerase in the presence (0.25, 0.75, 1.0, 3.0, or 5.0 µM) and absence of HapR. Except for the *VC1375* promoter, where the maximum HapR concentration was 3.0 µM. The RNAI transcript is plasmid-derived and acts as an internal control. Expected transcript sizes, based on results from global transcription start site mapping experiments[30], are indicated. Note that no *VC1403* transcript was detected in this prior study[30].

Figure 3: Transcription from the *murQP* promoter requires CRP *in vivo* and *in vitro*.

a. **HapR binding to the *murQP* regulatory region.** Genes are shown as block arrows. ChIP-seq coverage plots are shown for individual experimental replicates. Signals above or below the horizontal line correspond to reads mapping to the top or bottom strand respectively.
b. **DNA sequence of the intergenic region upstream of *murQP*.** For clarity, numbering is with respect to the *murQP* transcription start site (TSS, +1). The TSS and promoter -10 element are in bold. The *murQ* start codon is in blue. The HapR binding site, predicted by MEME analysis of our ChIP-seq data for HapR, is in green. A potential CRP site is embedded within the HapR

binding sequence (orange). Sequences in red indicate point mutations used in this work. Triangles show sites of truncation.

c. **Binding of CRP to the *murQP* regulatory region and derivatives.** Electrophoretic mobility shift assays showing migration of the *murQP* regulatory region, or indicated derivatives, with or without 0.1 µM CRP. The DNA fragment used is shown above each pair of lanes and correspond to the truncations or point mutations indicated in panel b.

d. **The *murQP* promoter is activated by CRP *in vitro*.** The gel image shows the result of an *in vitro* transcription assay. The DNA template was plasmid pSR carrying the *murQP* regulatory region. Experiments were done with 0.4 µM RNA polymerase with or without 0.125, 0.25, or 0.5 µM CRP. The RNAI transcript is plasmid-derived and acts as an internal control.

e. **The *murQP* promoter is activated by CRP *in vivo*.** The bar chart shows results of β-galactosidase activity assays. Cell lysates were obtained from wild type *V. cholerae* E7946 (solid green) or the Δ*crp* derivative, transformed with pRW50T derivatives containing the indicated promoter derivatives fused to *lacZ*. Standard deviation is shown for three independent biological replicates. Cells were grown in LB medium.

Figure 4: HapR and CRP co-operatively bind the same section of *murQP* regulatory DNA.

a. **Binding locations of HapR and CRP upstream of *murQP*.** The gel shows the result of DNase I footprinting experiment. The gel is calibrated with Sanger sequencing reactions. The pattern of DNase I cleavage in the absence of any proteins is in lane 1. Protection of DNA from DNase I cleavage in the presence of 0.11, 0.23 or 0.45 µM CRP is shown in lanes 2-4. Sites of DNAse I hypersensitivity due to CRP binding are indicated by orange triangles. Protection from DNase I cleavage in the presence of 0.5, 1.0, 2.0 or 3.0 µM HapR is shown in lanes 5-8. Protection from DNase I cleavage, dependent on HapR, is shown by a green bar. A DNAse I hypersensitive band, unique to reactions with HapR, is shown by a green triangle. In the presence of 0.45 µM CRP, increasing concentrations of HapR result in a different DNAse I cleavage pattern, including the appearance of a different site of hypersensitivity (black triangle).

b. **Binding of HapR and CRP upstream of *murQP* is co-operative.** Electrophoretic mobility shift assays showing migration of the *murQP* regulatory region with different combinations of CRP (0.025, 0.05, 0.1 or 0.2 µM) and HapR (0.5, 1.0, 2.0, 3.0 or 4.0 µM). For incubations with both factors, the same range of HapR concentrations was used with 0.2 µM CRP.

c. **Co-operative binding of CRP requires the shared HapR and CRP binding site.** Results of an electrophoretic mobility shift assay, using the wild type *murQP* regulatory region or a derivative with two point mutations in the shared recognition sequence, for HapR (4.0 µM) and CRP (0.1 µM). Positions of mutations are shown in Figure 3b.

d. **HapR blocks CRP mediated activation of the *murQP* promoter *in vitro*.** The gel image shows the result of an *in vitro* transcription assay. The DNA template was plasmid pSR carrying the *murQP* regulatory region. Experiments were done with 0.4 µM RNA polymerase, with or without 0.05, 0.1, 0.2 or 0.5 µM CRP 0.5, 1.0, 2.0 or 3.0 µM HapR, as indicated. The RNAI transcript is plasmid-derived and acts as an internal control.

e. **HapR represses CRP mediated activation of the *murQP* promoter *in vivo*.** β-galactosidase activity was measured in cell lysates taken from *Vibrio cholerae* E7946 (solid green bars), Δ*hapR* derivative (open green bars), Δ*crp* variant (open orange bars), or cells lacking both factors (orange outline with green patterned fill). Standard deviation is shown for three independent biological replicates. Cells were grown in LB medium.

Figure 5: HapR contacts Activation Region 3 of CRP.

a. **Binding sites for CRP and HapR are optimally aligned when offset by one base pair.** The panel shows DNA sequences logos generated by aligning binding sites identified by ChIP-seq analysis for CRP (top) and HapR (bottom). The centre of each motif is indicated by a dashed line.

b. **Global overlap of CRP and HapR binding sites.** A position weight matrix (PWM), corresponding to each DNA sequence logo shown in panel a, was created. The PWMs were used to search the *V. cholerae* genome sequence using FIMO. Distances between the identified CRP and HapR sites were calculated. Proximal sites were always overlapping and offset by one base pair (top panel). Overlap was greatly reduced when the analysis was applied to a randomised version of the same genome sequence (bottom panel).

c. **Model of the DNA-CRP-HapR complex**. The model was generated using PDB submissions 6pb6 (*E. coli* CRP in complex with a class II CRP dependent promoter) and 1jt0 (*S. aureus* QacR bound to its DNA target). Note that QacR is closely related to *V. cholerae* HapR. The structures were aligned so that the CRP and HapR binding centres were offset by one base pair. Residue E55 of CRP (blue) is within Activating Region 3 of CRP that can interact with the RNA polymerase sigma subunit at class II promoters. HapR residue R123 (red) participates in HapR dimerisation and is proximal to E55 of CRP.

d. **Side chain E55 of CRP is required for stability of the DNA-CRP-HapR complex.** Electrophoretic mobility shift assays showing migration of the *murQP* regulatory region with different combinations of CRP or CRP^{E55A} (0.15, 0.3 or 0.6 µM) and HapR (0.083, 0.125, 0.166 0.208 or 0.25 µM).

e. **HapR cannot repress transcription activated by CRP^{E55A}.** Result of an *in vitro* transcription assay. The DNA template was plasmid pSR carrying the *murQP* regulatory region. Experiments were done with 0.4 µM RNA polymerase, with or without 0.05, 0.1, 0.2 or 0.5 µM CRP or CRP^{E55A} and 0.5, 1.0, 2.0 or 3.0 µM HapR, in the presence of 0.2 µM CRP, as indicated. The RNAI transcript is plasmid-derived and acts as an internal control.

Figure 6: Control of *murQP* expression by CRP and HapR at low and high cell density.

a. ***V. cholerae* locked at high cell density are defective for growth using MurNAc as the sole carbon source.** Each panel illustrates the optical density of *V. cholerae* cultures at different timepoints after inoculation. Cells lacking *luxO*, but not *luxO* and *hapR*, mimic the high cell density state. Error bars show standard deviation from three separate experimental replicates.

b. **Model for coordination of MurNAc catabolism by CRP and HapR.** In low *V. cholerae* population density conditions (left panel) cell division necessitates cell wall turnover. Expression of MurQP facilitates cell wall recycling and conversion of MurNAc to GlcNAc 6P for glycolysis (insert). At high cell density conditions (right panel) *V. cholerae* form biofilms on chitinous surfaces. Reduced cell division, and the availability of chitin derived GlcNAc 6P, reduces the need for MurQP.

SUPPLEMENTARY FIGURE LEGENDS

Figure S1: Binding of LuxO and the *qrr1* and *VC1142* loci. ChIP-seq coverage plots are shown for individual experimental replicates. Signals above or below the horizontal line correspond to reads mapping to the top or bottom strand respectively.

Figure S2: Binding of HapR to the *hapR* promoter region in the presence and absence of CRP. Electrophoretic mobility shift assay showing migration of the *hapR* regulatory region with different combinations of CRP (0.0125, 0.025, 0.05 or 0.1 µM) and HapR (0.0625, 0.125, 0.25 or 0.5 µM). For incubations with both factors, the same range of HapR concentrations was used with 0.1 µM CRP.

Figure S3: Global overlap of CRP and HapR binding sites in *Vibrio harveyi*. A position weight matrix (PWM), corresponding to each DNA sequence logo shown in Figure 5a, was created. The PWMs were used to search the *V. harveyi* genome sequence (strain ATCC 33843) using FIMO. Distances between the identified CRP and HapR sites were calculated. Proximal sites were always overlapping and offset by one base pair (top panel). Overlap was greatly reduced when the analysis was applied to a randomised version of the same genome sequence (bottom panel).

Figure S4: Models of the DNA-CRP and DNA-CRP-HapR complexes. The models were generated using PDB submissions 6pb6 (*E. coli* CRP in complex with a class II CRP dependent promoter) and 1jt0 (S. aureus QacR bound to its DNA target). The DNA is shown in grey and positions hypersensitive to DNAse I cleave, in the context of the DNA-CRP complex, are highlighted red (Figure 4a). DNA position -34 is not cleaved by DNAse I in the context of the ternary DNA-CRP-HapR complex (Figure 4a). Consistent with this, position -34 is obscured by HapR binding.

Figure S5: Binding of CRP and HapR derivatives to P*murQP*. The figures shows results of electrophoretic mobility shift assays with CRP and derivatives (0.1, 0.2, 0.4 or 0.8 µM) or HapR and derivatives (0.25, 0.5, 1.0, 2.0 or 4.0 µM).

Figure S6: Co-operative DNA binding of HapR and CRP is common. Electrophoretic mobility shift assays showing migration of the indicated regulatory regions with different combinations of CRP (1 µM) and HapR (0.19 µM). For *VCA0691* the concentration of HapR was 0.57 µM.

Figure S7: Example HapR binding signals.

a. **Binding peaks for HapR that fall above our cut-off for peak selection.** The HapR ChIP-seq binding profiles are shown in green and genes are shown as blue arrows.
b. **Binding peaks for HapR, at known targets, that fall below our cut-off for peak selection.** Binding signals for HapR are shown at known target genes. These peaks for not selected by our analysis because the signal was too weak and/or insufficiently reproducible.

Figure S8: Original gel images.

Table 1: Locations of binding peaks from ChIP-seq experiments

peak centre	gene(s)[4]	site location	site sequence

HapR ChIP-seq peaks

chromosome I

99874	*VC0102*<(*VC0103*)	99863.5	aaattaataaaactgtcattta
213457	(*VC0205*)>*VC0206*	213452.5	taattgtgattcttatcaccaa
246366[1]	*VC0240*<>*VC0241*	246349.5	taattaagatggctataaacta
463584	*VC0433*		
514422	*VC0484*	514430.5	ctactgacctttcatcaataa
516570	(*VC0486*)	516601.5	caactgagaaggcacacaatag
534714	(*VC0502*)	534691.5	ctattataagctctatcagtgt
547108	*VC0515*	547135.5	atagtaatattattgttaatag
613328[3]	*VC0583*[A]	613357.5	ttattgagtgggtacataacaa
716707	*VC0668*	716625.5	ctattgatgaggttatccacag
735309	*VC0687*<>*VC0688*		
882854	(*VC0822*)	882825.5	taattatccactttatcaattg
941187	*VC0880*	941164.5	cttttgacatttctgtcacaaa
978577	*VC0916*[R]	978540.5	taattaatatccagctcaatta
1356743	*VC1280*<>*VC1281*[A]	1356736.5	atattgatagaaataacaagtc
1379202	*VC1298*<>*VC1299*	1379180.5	ttcatgatagttttgtaattat
1469384	*VC1375*<>*VC1376*	1469377.5	atattgatatatcacacatctt
1496023	*VC1403*[A]<(*VC1404*)>*VC1405*	1496025.5	tagttgatatttttataattgt
1533842	(*VC1437*)	1533854.5	tttgtgagtctcctgtcaataa
1990133[2]	*VC1851*	1990076.5	atattgagtaatcaattagtaa
2364721	(*VC2212*)	2364680.5	ctattaacagttttatttataa
2509878	*VC2352*	2509882.5	ttagtgacagatgcgtcattaa
2667349	*VC2486*	2667368.5	taattattaatttgaacaatag

chromosome II

163808[1]	*VCA0148*	163810.5	taattgattattgtgtaactat
214589	(*VCA0198*)	214582.5	taattgataactttgacagtat
237008	*VCA0218*<>*VCA0219*[R]	237019.5	taaataatatgaatatcagtaa
247286	*VCA0224*<>*VCA0225*	247241.5	taaatgactaataagacaatta
598444	*VCA0662*<>*VCA0663*[R]	598403.5	tttgtaataaatttgtcattaa
630517	*VCA0691*[A,]	630559.5	ctattaacaggactgacattaa
862737	*VCA0906*		
910196	*VCA0960*[R]<>*VCA0961*	910181.5	ctgattataaatttgtaaatat
1021174	*VCA1070*	1021117.5	ctcctatccgattggtcactat

LuxO ChIP-seq peaks

chromosome I

1090129	*qrr1*<> *VC1021*	1090154	ttgcaaaatgcaa
1212442	*VC1142*<>*VC1143*	1212435	ttgcaaatcgcga

chromosome II

48415	*qrr2*	48347	ttgcaatttgcaa
772208	*qrr3*	772149	ttgcattttgcaa
908445	*qrr4*	908436	ttgcaatttgcaa

[1]Identified by Tsou and co-worlers[28]
[2]Identified by Waters and co-workers[29]
[3]Identified by Lin and co-workers[27]
[4]Identified as activated (A) or repressed (R) by Nielsen and co-workers[23]

Figure 1


a
Low Cell Density
phosphate flow
LuxO-P
up regulation
Qrr sRNAs
down regulation
hapR mRNA
High Cell Density
LuxO
hapR mRNA
HapR
regulation of target genes
b
Vibrio cholerae E7946 chromosome I
qrr1
Vibrio cholerae E7946 chromosome II
qrr2
qrr3
qrr4
genes
LuxO ChIP-seq
HapR ChIP-seq
c
LuxO ChIP-seq
replicate 1
replicate 2
control ChIP-seq
qrr2
VCA0041
HapR ChIP-seq
replicate 1
replicate 2
control ChIP-seq
VC1403
VC1405
d
Motif derived from 5 LuxO ChIP-seq peaks
bits
position
Motif derived from 32 HapR ChIP-seq peaks
bits
position
e
number of peaks
LuxO peaks
distance to nearest start codon
gene
number of peaks
HapR peaks
distance to nearest start codon
gene
f
gene regulation
metabolism
unknown
metabolism
gene regulation
motility and chemotaxis
DNA repair
cell signalling
virulence
structural

Figure 2

a


β-galactosidase activity (Miller units)
2500
2000
1500
1000
500
0
wild type
ΔhapR
no insert
PVC0443
PVC0620
PmutH
PVC1436
PVCA0218
PVCA0662
PVCA0961
PmurQP
PhapR
PVC0585
PVC2352
PVCA0219
PVCA0663
PVCA0960
PVC1375
PVC1403
PrfaD
PVC0241
PVC0502
PVC0688
PVC1298
PVC1376
PVC1405
PVCA0906
PVCA0960
inactive
repressed
activated
unresponsive
promoter::lacZ fusion

b


[HapR]
350 nt
300 nt
250 nt
220 nt
200 nt
190 nt
180 nt
170 nt
160 nt
150 nt
140 nt
130 nt
120 nt
110 nt
100 nt
90 nt
116 nt
169 nt
136 nt
176 nt
532 nt
164 nt
210 nt
400 nt
RNAI
Lane
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53
% of maximum activity for each promoter
no transcript
100 93 88 93 77 74
100 100 100 98 83 54
100 100 100 100 71 43
100 38 16 30 10 3
100 77 61 28 18 9
100 100 93 71 59 47
38 42 62 58 100
no transcript
PmurQP
PhapR
PVC0585
PVC2352
PVCA0219
PVCA0663
PVCA0960
PVC1375
PVC1403
expected transcript size (nucleotides)
in vitro transcription template

Figure 3

a



b



c



d



e



Figure 4


a
markers
C T A G
[HapR]
[CRP]
-150
-140
-130
-120
-110
-100
-90
-80
-70
-60
-50
-40
-30
-20
-10
+1
+10
+20
Lane 1 2 3 4 5 6 7 8 9 10 11 12
b
[HapR]
[CRP]
HapR-CRP-DNA
CRP-DNA
PmurQP DNA
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
c
wild type
-49g -35g
HapR
CRP
HapR-CRP-DNA
CRP-DNA
PmurQP DNA
Lane 1 2 3 4 5 6 7 8
d
marker
[HapR]
[CRP]
120 nt
110 nt
100 nt
PmurQP RNA
RNAI
Lane 1 2 3 4 5 6 7 8
% of max. activity 0 100 98 85 79 40 15 10
e
β-galactosidase activity (Miller units)
900
600
300
0
wild type
ΔhapR
Δcrp
ΔcrpΔhapR
V. cholerae strain

Figure 5

a

Alignment of CRP (top) and HapR (bottom) binding motifs



b



c



d



Lane	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
% of CRP-DNA complex bound by HapR	N/A	N/A	N/A	N/A	52	69	100	100	100	N/A	N/A	N/A	N/A	36	50	53	79	91
CRP derivative	wild type									E55A								

e



Lane	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
% of max. activity for each CRP derivative	0	77	100	81	34	11	10	2	2	0	5	18	44	100	47	41	26	20	0	0	13	44	100	47	39	30	29
CRP derivative	wild type									E55A									E55R								

Figure 6

a


wild type
ΔluxO
ΔhapR
ΔluxOΔhapR
ΔmurQP
M9 minimal media + MurNAc
M9 minimal media + glucose
LB media
OD600
Time (minutes)

b


murQP
CRP
glycolysis
GlcNAc 6P
cell wall recycling
Low cell density
chitin oligosaccharides
HapR
murQP
CRP
glycolysis
GlcNAc 6P
High cell density

Figure S1



Figure S2



Figure S3


V. harveyi genome sequence
+1 bp
HapR
201
8
CRP
101
V. harveyi scrambled sequence
HapR
132
1
CRP
137
Number of biding sites
Distance between HapR and CRP sites
-100
0
100
0
1
2
3
4
5
6
7
8
9

Figure S4


a
CRP
-34
-38
180°
-34
-47
-38
DNAse I hypersensitivity
b
HapR
180°
-47
-38

Figure S5


[CRP]
HapR-DNA
PmurQP DNA
CRPWT
CRPE55A
CRPE55R
[HapR]
HapR-DNA
PmurQP DNA
HapRWT
HapRR123A
HapRR123E

Figure S6


VC0102<(VC0103)
VC1851
VCA0218<>VCA0219
VCA0663
VCA0691
CRP
HapR
Lane
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
DNA
HapR-DNA
CRP-DNA
HapR-CRP-DNA

Figure S7

a


VC1405
VCA0689
VC0583
(hapR)

b


VC0865
(hapA)
VCA0952
(vpsT)
VCA0246
VC1213

Figure S8

Figure 2b



Figure 3c





Figure 3d



Figure 4a



Figure 4b



Figure 4d



Figure 4c





Figure 5d



Figure 5e



Figure S2



Figure S5





Figure S6